#CHAIR2016. September 15 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
|
|
- Rolf Dalton
- 5 years ago
- Views:
Transcription
1 #CHAIR2016 September 15 17, 2016 The Biltmore Hotel Miami, FL Sponsored by
2 #CHAIR2016 Parkinson s Disease Psychosis: The Latest Evidence for Screening and Treatment Stuart Isaacson, MD FIU Herbert Wertheim College of Medicine Boca Raton, FL
3 Stuart Isaacson, MD Disclosures Research/Grants: ACADIA Pharmaceuticals Inc. Consultant: ACADIA Pharmaceuticals Inc. Speakers Bureau: ACADIA Pharmaceuticals Inc.
4 #CHAIR2016 Learning Objective 1 Screen all Parkinson s disease (PD) patients for neuropsychiatric symptoms, such as psychosis, at regular intervals.
5 #CHAIR2016 Learning Objective 2 Engage patients and caregivers to develop strategies to help manage the impact of PD psychosis on daily functioning.
6 #CHAIR2016 Learning Objective 3 Describe the current best practice and emerging treatment approaches for the clinical management of PD psychosis.
7 Parkinson s Disease: Introduction Parkinson s disease (PD) is the second most common neurodegenerative disorder and affects about 1 million persons in the US While PD is known for its motor symptoms, many nonmotor neuropsychiatric symptoms occur such as sleep, cognitive, and autonomic dysfunction Non-motor symptoms have a significant impact on quality of life Jankovic J. J Neurol Neurosurg Psychiatry. 2008;79(4): Bernal-Pacheco. O, et al. Neurologist. 2012;18(1):1-16.
8 Overview A single cause for PD has not been found Involves selective degeneration of the nigrostriatal pathway with reduction in the striatal concentration of dopamine Many non-motor features of PD relate to degeneration of non-dopaminergic transmitter systems, including norepinephrine and serotonin Obeso JA, et al. Nat Med. 2010;16(6): Lang AE, et al. Lancet Neurol. 2004;3(5):
9 Decline of Striatal Dopamine Innervation Striatal dopamine innervation assessed by 18 F-dopa PET Controls (n = 8) Patient with PD Obeso JA, et. al. Nat Med. 2010;16(6):
10 Parkinson s Disease Therapies The range of pharmacologic therapies for PD is wider than other neurodegenerative diseases Levodopa Dopamine agonists Monoamine oxidase (MAO) B inhibitors Catechol-O-methyl transferase (COMT) inhibitors Anticholinergic agents Amantadine Connolly BS,. Lang AE. JAMA. 2014;311(16):
11 Motor and Non-Motor PD Symptoms Motor Symptoms Resting tremor Rigidity Bradykinesia Postural instability Festinating gait Micrographia Masked facies Retropulsion Hypophonic speech Non-motor Symptoms Constipation Autonomic dysfunction Impaired olfaction Dementia Depression Sleep disorders Impulse control disorders Psychosis Jakel RJ, Stacy. M. Journal of Parkinsonism and Restless Legs Syndrome. 2014;4:41-51.
12 Parkinson s Disease: Neuropsychiatric Disorder? Anxiety Depression Executive function, cognitive impairment, dementia Apathy Compulsive disorders PD psychosis ***Affects QOL and associated with significant burden on patients, families, and caregivers Forsaa EB, et al. Arch Neurol. 2010;67(8): Schrag A, et al. Parkinsonism Relat Disord. 2006;12(1):35-41.
13 PD Psychosis is Underreported Only 10% to 20% of patients spontaneously report symptoms to the physicians Patients may be reluctant to disclose their psychosis symptoms due to stigma and fear of hospitalization Patients may not be aware that psychosis symptoms are due to their Parkinson s disease Caregivers may be unaware of symptoms until they become distressful Chaudhuri KR, et al. Mov Disord. 2010;25(6): Fénelon G, et. al. J Neurol Sci. 2010;289(1-2):12-17.
14 Incidence of PD Psychosis Population-based prevalence cohort study (n = 230) PD patients followed prospectively for 12 years Point prevalence was 17.8% at baseline and increased to 48% at 12 years 60% of patients developed PD psychosis over the course of their disease Incidence of PD psychosis was 79.7 per 1,000 personyears Forsaa EB, et. al. Arch Neurol. 2010;67(6):
15 Prevalence of Hallucinations in PD Reference n Total Prevalence (%) Williams et al, Pacchetti et al, Paleacu et al, Bailbé et al, Schrag et al, Fénelon et al, Aarsland et al, Inzelberg et al, Graham et al, Sanchez-Ramos et al, Fénelon G. CNS. Spectr. 2008;13(3 suppl 4):18-25.
16 Risk Factors for PD Psychosis Risk Factor Advancing age Cognitive decline Duration and severity of illness Severity of illness Treatment with dopaminergic agonists Presence of sleep disorders Presence of other psychiatric conditions (apathy, depression) Jakel RJ, Stacy M. Journal of Parkinsonism and Restless Legs Syndrome. 2014;4:41-51.
17 Pathophysiology of PD Psychosis Multiple neurochemical and neuropsychological abnormalities; no single brain structure involved Sleep dysregulation, sleep fragmentation, and altered dream phenomena Abnormalities of visual processing may contribute to hallucinations Latoo J, et al. Prog Neurol Psychiatry. 2012;16(5):4-35. Arnuf I, et al.. Neurol. 2000;55(2): Wint DP, et al. J Geriatr Psychiatry Neurol. 2004;17(3):
18 Intrinsic and Extrinsic Dimensions of PD Psychosis INTRINSIC EXTRINSIC Visual dysfunction Environment Neurochemical abnormalities Brainstem/ sleep dysfunction Cortical pathology PD Psychosis PD medications Other psychiatric conditions Hindle JV. J Neural Transm. 2013;120(4):
19 Pathophysiology of PD Psychosis: Neurotransmitters Excessive dopaminergic activity, particularly in the mesocortical and mesolimbic systems contributes to hallucinations Dopamine is not the only factor (drug-naive patients with PD report hallucinations) Serotonin is disrupted in PD, with extensive loss of serotonergic raphe neurons The role of acetylcholine is under investigation; marked degeneration of cholinergic neurons is evident in brains of patients with PD Wint DP, et al.. J Geriatr Psychiatry Neurol. 2004;17(3):
20 Serotonin is Disrupted in PD The serotonergic system is disrupted in PD Patients with PD have reduced serotonin transporter binding PD = Parkinsons disease NC = Normal control Albin RL, et al.. J Cerebral Blood Flow Metab. 2008;28:
21 Mechanisms Of Visual Hallucinations in Parkinson s Disease Complex visual hallucinations are probably related to abnormal activity in the ventral extrastriate visual cortex May result from various and concomitant mechanisms including Dopaminergic overactivity Overactivity and/or imbalance in monaminergic and cholinergic neurotransmission Alteration of brain stem wake and dream regulation Dysfunction of visual pathways Nonspecific coincidental ocular disease such as Parkinson s diseaseassociated retinal dysfunction and functional alterations in the ventral stream of visual cortical pathways Fénelon G. CNS. Spectr. 2008;13(3 suppl 4):18-25.
22 Prevalence of Psychosis Symptoms Symptom Fénelon G, et al. Mov Disord. 2010;25(6): Fénelon G, et al. J Neurol Sci. 2010;289(1-2): Prevalence Visual hallucinations 16% to 38% Illusions, passage, presence 17% to 72% Auditory hallucinations 0% to 22% Delusions (reference, persecutory, jealousy) 1% to 14% Tactile hallucinations 12% Olfactory hallucinations 11% Gustatory hallucinations 3% Somatic hallucinations 1%
23 The Concept of Benign Hallucinations is Misleading Study of 48 patients with benign hallucinations and Unified Parkinson s Disease Rating Scale (UPDRS) scores during 3 yr follow-up Goetz CG, et al. Arch Neurol. 2006;63(5): % of patients progressed to UPDRS scores of 3 or 4 Progression of PD from a baseline UPDRS score of 2 (benign hallucinations, insight retained) to a UPDRS score of 3 or 4 (loss of insight, delusions)
24 The Course of PD Psychosis Hallucinations begin Insight is retained Hallucinations progress Insight is lost Onset of delusions. Nursing home placement Aarsland D, et al. J Am Geriatr Soc. 2000;48(8): ; Chaudhuri KR, et al. Lancet Neurol. 2006;5(3): ;Goetz CG, et al. Arch Neurol. 2006;63(5): ; Jakel RJ, Stacy M. Journal of Parkinsonism and Restless Legs Syndrome 2014;4:41-51.
25 Phenomenology: Visual Hallucinations Usually persons (living or deceased) May be animals or objects Superimposed on real background Moving or blurred Appear suddenly Usually vanish rapidly Patient usually observer rather than actor Fénelon G. CNS Spectr. 2008;13(3 suppl 4):18-25.
26 Phenomenology: Auditory Hallucinations Elementary (ringing, knocks, etc) or complex Verbal, usually neutral or incomprehensible Conversations of unreal persons Differ from those of schizophrenia not pejorative or threatening Fénelon G. CNS Spectr. 2008;13(3 suppl 4):18-25.
27 Phenomenology: Other Hallucinations Tactile Contact with small animals Being touched by someone Often combined with other types of hallucinations Olfactory and gustatory Illusions (mistaken identification of actual stimuli) Presence or passage (perception of object or person in visual periphery) Fénelon G. CNS Spectr. 2008;13(3 suppl 4):18-25
28 Differential Diagnosis of PD Psychosis Medical conditions Delirium Infection Drug toxicity Dehydration Nutritional deficiencies Thyroid dysfunction Psychiatric conditions Schizophrenia Major depression with psychosis Bipolar disorder with psychosis Neurodegenerative conditions Lewy body dementia Alzheimer s disease psychosis Ravina B, et. al. Mov Disord. 2007;22(8):
29 NINDS-NIMH Diagnostic Criteria Characteristic symptoms of psychosis (at least 1) Illusions False sense of presence Hallucinations Delusions Characteristic symptoms of PD Chronology: Symptoms of psychosis must occur after diagnosis of PD Duration: Symptoms of psychosis must be recurrent or continuous for 1 mo. Other potential causes must be eliminated Associated features Insight Dementia Anti-parkinson medications Ravina B, et al. Mov Disord. 2007;22(8):
30 Managing PD Psychosis Medication review and evaluate systemic triggers Urinary and other infections, dehydration, sleep change Adjust parkinsonian medications Suggested sequence: anticholinergics, amantadine, selegiline, dopamine agonists Important consequence of PDP is suboptimal motor treatment! Antipsychotics may be helpful but may be associated with worsening of motor function Pimavanserin is the only medication approved by the FDA for Parkinson s psychosis Jakel RJ, Stacy M. Journal of Parkinsonism and Restless Legs Syndrome 2014;4:41-51.
31 Antipsychotic Adverse Effects Atypical antipsychotics have black box class warning for increased mortality in elderly with dementia Efficacy unclear for PDP, except for clozapine and pimavanserin Antipsychotics can cause postural hypotension and sedation All current antipsychotics (except pimavanserin) block post synaptic D2 receptors and can worsen motor Parkinsonism Friedman PD, et al. N Engl J Med. 1999;340(10): Jakel RJ, Stacy M. Journal of Parkinsonism and Restless Legs Syndrome 2014;4:41-51
32 Richard IH, Nutt J. Neurology. 2000;55(6):
33 Movement Disorder Society EBM Recommendations Agent Clozapine Quetiapine Olanzapine Recommendation Efficacious, acceptable risk with specialized monitoring (risk of agranulocytosis) Insufficient evidence for efficacy, acceptable risk without specialized monitoring Unlikely to be efficacious with unacceptable risk (worsening movement symptoms) Seppi K, et al.. Mov Disord. 2011;26(Suppl 3):S42-S80
34 Clozapine* Efficacy Experimental Study or Subgroup Mean s.d. Total Control Mean s.d. Total Weight (%) Mean Difference IV, Random, 95% Cl Mean Difference IV, Random, 95% Cl Parkinson Study Group [-1.24, -0.96] Pollack [-1.76, -0.24] Total (95% Cl) [-1.23, -0.96] Heterogeneity: Tau 2 = 0.00; χ 2 = 0.06, df = 1 (P = 0.80); I 2 = 0% Test for overall effect: Z = (p <.00001) Favours [experimental] Favours [control] Clozapine associated with agranulocytosis in ~1% of patients; requires regular blood monitoring *Not FDA approved for the treatment of PDP. Friedman PD, et al. N Engl J Med. 1999;340(10): Pollak P, et al. J Neurol Neurosurg Psychiatry. 2004;75(5):
35 Quetiapine* Efficacy Study N Outcomes Morgante et al, Significant improvement in BPRS and CGI-S (P<0.001 for each); no significant improvement in UPDRS Ondo et al, No significant improvement in BPRS or BPDHQ Merims et al, Significant improvement CGIC (P<0.05) Rabey et al, No significant improvement in BPRS or CGI-S Kurlan et al, No significant improvement in BPRS Fernandez et al, Significant improvement in CGI-S or BPRS (P<0.05) Shobolt P et al, No significant improvement in BPRS or BPDHQ BPRS = Brief Psychiatry Rating Scale; CGI-S = Clinical Global Impression Scale-Severity Subscale; BPPHQ = Baylor Parkinson s Disease Hallucination Scale; CGIC = Clinical Global Impression of Change *Not FDA approved for the treatment of PDP Desmarais P, et al. J Geriatr Psychiatry Neurol. 2016;29(4):
36 Pimavanserin Clinical Study Pimavanserin is a selective serotonin inverse agonist High affinity for 5-HT2A; no appreciable affinity for dopaminergic, muscarinic, histaminergic, or adrenergic receptors Placebo controlled, randomized, parallel group of 199 patients with PD psychosis that evaluated pimavanserin 40 mg or placebo Symptoms of 1 mo. duration, at least weekly Primary endpoint change from baseline in Scale for Assessment of Positive Symptoms-PD (SAPS-PD) Only FDA-approved treatment for PD psychosis Cummings J et, al. Lancet. 2014;383(9937):
37 Inverse Agonists Have Negative Intrinsic Activity Hanania NA. Curr Opin Pulm Med. 2010;16:1-5.
38 SAPS-PD The Scale for Assessment of Positive Symptoms (SAPS) is reliable in PD populations and is recommended for use in PD psychosis SAPS is a structured clinical interview and covers 35 items; originally developed for schizophrenia A shortened, 9-item PD-specific version of SAPS is appropriate for assessing PD psychosis (SAPS-PD) Voss T, et al. Parkinsonism Relat Disord. 2013;19(3):
39 Pimavanserin: SAPS-PD Change from Baseline Pimavanserin resulted in a significant 37% improvement in SAPS-PD vs 14% for placebo (p = 0.006) No change in motoric function by UPDRS (parts 2 + 3) UPDRS = Unified Parkinson s Disease Rating Scale Cummings J, et al. Lancet. 2014;383:
40 Primavanserin: CGI Change From Baseline Significant improvements were observed in CGI-S and CGI-I scores CGI-S Cummings J, et al. Lancet. 2014;383: CGI-I 41
41 Primavanserin vs Placebo AE s Occurring in 5% in Either Group Adverse Event (AE) Placebo (n = 94) Pimavanserin (n = 104) Nausea 6% 6% Peripheral edema 3% 7% Urinary tract infection 12% 13% Fall 9% 11% Confusional state 3% 6% Headache 5% 1% Hallucination 4% 7% Cummings J, et al. Lancet. 2014;383:
42 Patient and Caregiver Disclosure Patients and caregivers may be hesitant to disclose symptoms of psychosis Important to ask about symptoms at each visit and early in the disease process Patients need education about PD psychosis symptoms and their relationship to PD Asking appropriate questions, probing in nonthreatening manner All sensory modalities Evaluate hallucinations, delusions, and other psychiatric conditions (passage or presence) Chaudhuri KR, et al. Mov Disord. 2010;25(6): ; Goetz CG, et al. Arch Neurol. 2006;63(5): ; Mack J, et al. Am J Geriatr Psychiatry. 2012;20(2):
43 Clinical Connections Psychosis is a common feature of the PD disease course Healthcare providers should be proactive and ask patients with PD about psychosis symptoms There are no benign hallucinations as PD psychosis is a progressive disorder Because it is progressive, diminishes QOL, and increases caregiver burden, treatment of Parkinson s Disease psychosis should not be delayed
44 #CHAIR2016 Questions Answers &
Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis
Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Jeff Gelblum, MD Senior Attending Neurologist Mt. Sinai Medical Center Miami,
More informationParkinson s Disease Psychosis:
Parkinson s Disease Psychosis: What Mental Health Professionals Need to Know Rajeev Kumar, MD Medical Director Rocky Mountain Movement Disorders Center Huntington s Disease Society of America Center of
More informationSTART THE CONVERSATION
START THE CONVERSATION ABOUT PARKINSON S DISEASE PSYCHOSIS Your patients with Parkinson s disease (PD) psychosis may be hesitant to report their symptoms LEARN MORE about how to identify the symptoms of
More informationPsychiatric aspects of Parkinson s disease an update
Psychiatric aspects of Parkinson s disease an update Dr Chris Collins 027 2787593 chris.collins@cdhb.health.nz Disclosures: none Non-motor aspects physical Sensory anosmia, visual symptoms Speech and
More informationCorporate Presentation August 6, 2015
Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationSenior Care South Florida September 16, Manju T. Beier, Pharm D, CGP, FASCP
Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations Manju T. Beier, Pharm D, BCGP, FASCP Senior Partner, GCR LLC Adjunct Clinical Associate Professor of Pharmacy
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationPSYCHOSIS IN PARKINSON'S DISEASE
PSYCHOSIS IN PARKINSON'S DISEASE Objectives Identify neurobiological substrates associated with Parkinson s disease psychosis Describe the differences between older antipsychotics and novel therapies for
More informationPimavanserin Top-Line Results Phase III Parkinson s Disease Psychosis Trial (-020 Study) Creating the Next Generation of CNS Drugs
Pimavanserin Top-Line Results Phase III Parkinson s Disease Psychosis Trial (-020 Study) Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements.
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationMaking Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease
Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the
More informationAlison Charleston 1 st September 2016
Alison Charleston 1 st September 2016 Clinical features of Parkinson s disease Differential diagnosis Management of the motor features Non-motor and neuropsychiatric aspects 100-200 per 100,000 prevalence
More informationClinical Features and Treatment of Parkinson s Disease
Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and
More informationNew Drug Evaluation: pimavanserin tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationParkinson s Disease Psychosis: Hallucinations Delusions and Paranoia
Parkinson s Disease Psychosis: Hallucinations Delusions and Paranoia Christopher G. Goetz, MD Professor of Neurological Sciences Professor of Pharmacology Rush University Medical Center Parkinson s Foundation
More informationThe Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia
Disclosures Research support, Parkinson Society Canada, Canadian Institutes of Health Research, Ministry of Economic Development and Innovation, Teva Novartis clinical trial, Principal Investigator CME
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationEvaluation of Parkinson s Patients and Primary Care Providers
Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,
More informationDisclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
More informationBehavioral Aspects of Parkinson s Disease
Behavioral Aspects of Parkinson s Disease Joseph H. Friedman, MD Director, Movement Disorders Program Butler Hospital Dept of Neurology Alpert Medical School of Brown University 1 Disclosures Drugs will
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationRasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature
Neurol Ther (2014) 3:41 66 DOI 10.1007/s40120-013-0014-1 REVIEW Rasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature Michele Pistacchi Francesco Martinello Manuela
More informationDRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer
DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with
More informationEvaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
More informationManagement of Psychosis in Parkinson Disease
May 01, 2014 By Howard D. Weiss, MD [1] and Sam Adler, MD [2] For some patients with Parkinson disease, the neuropsychiatric complications are a greater source of morbidity than the motor dysfunction.
More informationCommonly encountered medications and their side effects - what the generalist needs to know
Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and
More informationAny interventions, where RCTs in PD are not available, are not included in the tables.
Tables Interventions where new studies have been published are indicated in bold italics. Changes in conclusions are indicated in italics and are highlighted in yellow. Any interventions, where RCTs in
More informationNon-motor symptoms in Thai Parkinson s disease patients: Prevalence and associated factors
Neurology Asia 2018; 23(4) : 327 331 Non-motor symptoms in Thai Parkinson s disease patients: Prevalence and associated factors Kusuma Samart MD Department of Medicine, Surin Hospital, Surin Province,
More informationParkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee
Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is
More informationNuplazid. Nuplazid (pimavanserin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.03 Subject: Nuplazid Page: 1 of 4 Last Review Date: June 22, 2018 Nuplazid Description Nuplazid (pimavanserin)
More informationParkinson s disease (PD) affects approximately 1 million people in the United States, and more than
December 2016 PRESENTER Daniel E. Kremens, MD, JD Associate Professor of Neurology Co-Director, Parkinson s Disease and Movement Disorders Sidney Kimmel Medical College Thomas Jefferson University Philadelphia,
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More informationIs Safinamide Effective as an Add-on Medication in Treating Parkinson's Disease Motor Symptoms?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Is Safinamide Effective as an Add-on
More informationEvaluations & CE Credits
Evaluations & CE Credits Nursing Contact Hours, CME, CHES and Social Work credits are available. Please visit www.phlive.org to fill out your evaluation and complete the post-test. 1 The Psychiatric Symptoms
More informationParkinson s disease psychosis as a serotonin-dopamine imbalance syndrome
CNS Spectrums (2016), 21, 355 359. Cambridge University Press 2016 doi:10.1017/s1092852916000602 Parkinson s disease psychosis as a serotonin-dopamine imbalance syndrome Stephen M. Stahl ISSUE: Parkinson
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationPsychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More informationComprehensive Approach to DLB Management
Comprehensive Approach to DLB Management Bradley F. Boeve, MD Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Comprehensive Approach to DLB Management Disclosures
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationParkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle
Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non
More informationUnderstanding Hallucinations and Delusions in Parkinson s Disease
Understanding Hallucinations and Delusions in Parkinson s Disease A Discussion Guide for Healthcare Professionals, Residents, and Caregivers WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED
More informationParkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations
Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations Pari Deshmukh MD Triple board-certified psychiatrist (Boards of psychiatry, addiction medicine, integrative
More informationParkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even
More informationONCE-DAILY DOSING WITH NUPLAZID
YOUR GUIDE TO ONCE-DAILY DOSING WITH NUPLAZID NUPLAZID (pimavanserin) is the first and only FDAapproved treatment for hallucinations and delusions associated with Parkinson s disease psychosis 1 Indication
More informationClinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease
Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More informationHistory Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
More informationParkinson s Disease. Patients will ask you. 8/14/2015. Objectives
Parkinson s Disease Jean Van Kingsley MS, FNP-BC Objectives Describe the pathophysiolgy of PD. Review clinical charachteristics of PD. Identify management strategies, to maximize functional status. Recognize
More informationPsychobiology Handout
Nsg 85A / Psychiatric Page 1 of 7 Psychobiology Handout STRUCTURE AND FUNCTION OF THE BRAIN Psychiatric illness and the treatment of psychiatric illness alter brain functioning. Some examples of this are
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Redefining Parkinson s disease 1. Common non-motor features that precede the motor findings in Parkinson s disease (PD) include all of the following except?
More informationManagement of the Acutely Agitated Long Term Care Patient
Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia
More informationThe PD You Don t See: Cognitive and Non-motor Symptoms
The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver Goals
More informationMastering Your Anxiety in Parkinson s Disease
Mastering Your Anxiety in Parkinson s Disease Julie Alberty, Ph.D. Krista Hanson, Ph.D. Anxiety is common in persons with Parkinson s disease Prevalence of Anxiety in PD Higher rates than the general population,
More information6/19/18. Objectives. Disclosures. Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations
Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations Dana Saffel, PharmD, BCGP, CPh, FASCP President, CEO PharmaCare Strategies, Inc. June 24, 2018 Objectives
More informationThe Effect of Pramipexole on Depressive Symptoms in Parkinson's Disease.
Kobe J. Med. Sci., Vol. 56, No. 5, pp. E214-E219, 2010 The Effect of Pramipexole on Depressive Symptoms in Parkinson's Disease. NAOKO YASUI 1, KENJI SEKIGUCHI 1, HIROTOSHI HAMAGUCHI 1, and FUMIO KANDA
More informationAnticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:
More informationBEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationPresented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationReview Article Management of Psychosis in Parkinson s Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition
Hindawi Parkinson s Disease Volume 2017, Article ID 3256542, 18 pages https://doi.org/10.1155/2017/3256542 Review Article Management of Psychosis in Parkinson s Disease: Emphasizing Clinical Subtypes and
More informationscr.zacks.com 111 North Canal Street, Chicago, IL (ACAD-NASDAQ) NOTE ZACKS ESTIMATES
Small-Cap Research November 27, 2012 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Acadia Pharmaceuticals, Inc. (ACAD-NASDAQ) ACAD: Phase
More informationThe PD You Don t See: Cognitive and Non-motor Symptoms
The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Assistant Professor of Neurology and Psychiatry University of Colorado Denver Goals 1) What are the most common non-motor
More informationParkinson s Disease. Sirilak yimcharoen
Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically
More informationDIFFERENTIAL DIAGNOSIS SARAH MARRINAN
Parkinson s Academy Registrar Masterclass Sheffield DIFFERENTIAL DIAGNOSIS SARAH MARRINAN 17 th September 2014 Objectives Importance of age in diagnosis Diagnostic challenges Brain Bank criteria Differential
More informationPharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018
Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology UNTHSC Center for Geriatrics 855 Montgomery Street, PCC 4, Ft.
More informationNuplazid. (pimavanserin) New Product Slideshow
Nuplazid (pimavanserin) New Product Slideshow Introduction Brand name: Nuplazid Generic name: Pimavanserin Pharmacological class: Atypical antipsychotic Strength and Formulation: 17mg; tablets Manufacturer:
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More informationUnited Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline
United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline REV 3/24/09 The UCNS Geriatric Neurology examination was established to determine the level of competence
More informationBehavioral Issues in Dementia. March 27, 2014 Dylan Wint, M.D.
Behavioral Issues in Dementia March 27, 2014 Dylan Wint, M.D. OVERVIEW Key points Depression Definitions and detection Treatment Psychosis Definitions and detection Treatment Agitation SOME KEY POINTS
More informationDrugs used in Parkinsonism
Drugs used in Parkinsonism قادة فريق علم األدوية : لي التميمي & عبدالرحمن ذكري الشكر موصول ألعضاء الفريق املتميزين : جومانة القحطاني ندى الصومالي روان سعد القحطاني pharma436@outlook.com @pharma436 Your
More informationPARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information
OHSU PARKINS ON CENTER Parkinson s Disease: Diagnosis and Management for Every MD Disclosure Information Grants/Research Support: National Parkinson Foundation, NIH, Michael J. Fox Foundation Consultant:
More informationSupportive Neurology: Valuing Increased Function and Improved QoL in Treatment of Non-Core Symptoms of Neurological Disease
Supportive Neurology: Valuing Increased Function and Improved QoL in Treatment of Non-Core Symptoms of Neurological Disease Ginger S. Johnson, PhD Vice President Defined Health Todd Sherer, PhD Chief Executive
More informationNature, prevalence and clinical significance. Barcelona, Spain
Nature, prevalence and clinical significance Jaime Kulisevsky Barcelona, Spain 1 Non motor (neuropsychiatric) symptoms are an integral part of Parkinson s s disease (PD) Affective disorders And are associated
More informationWESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS
WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS DOPAMINE HYPOTHESIS Excessive limbic dopamine is hypothesised to cause psychosis Many antipsychotics inhibit dopamine 2 receptors in mesolimbic and
More informationHDSA welcomes you to Caregiver s Corner. Funded by an educational grant from
HDSA welcomes you to Caregiver s Corner Funded by an educational grant from Caregiver s Corner Webinar, DATE Managing Psychiatric Symptoms Peg Nopoulos, M.D. Professor of Psychiatry, Neurology, and Pediatrics
More informationHow to Effectively Manage the Motor Symptoms of HD
How to Effectively Manage the Motor Symptoms of HD Yvette Bordelon, MD, PhD Associate Clinical Professor of Neurology David Geffen School of Medicine at UCLA The information provided by speakers in workshops,
More informationParkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10
More informationAntidepressants. Dr Malek Zihlif
Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric
More informationMargo J Nell Dept Pharmacology
Margo J Nell Dept Pharmacology 1 The extra pyramidal system Separation of cortico-spinal system (pyramidal system, (PS)) from the basal ganglia (extra pyramidal motor system (EPS)) because they produce
More information8/28/2017. Behind the Scenes of Parkinson s Disease
BEHIND THE SCENCES IN Parkinson s Disease Behind the Scenes of Parkinson s Disease Anna Marie Wellins DNP, ANP C Objectives Describe prevalence of Parkinson's disease (PD) Describe the hallmark pathologic
More informationParkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease Initial Clinical and Diagnostic Evaluation J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More informationM. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment
M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz Parkinson s Disease A Guide to Medical Treatment SEEd srl. All rights reserved Piazza Carlo Emanuele II, 19 10123 Torino, Italy Tel. 011.566.02.58
More information10/13/2017. Disclosures. Deep Brain Stimulation in the Treatment of Movement Disorders. Deep Brain Stimulation: Objectives.
Deep Brain Stimulation in the Treatment of Movement Disorders Disclosures None Eleanor K Orehek, M.D. Movement Disorders Specialist Noran Neurological Clinic 1 2 Objectives To provide an overview of deep
More informationChapter 161 Antipsychotics
Chapter 161 Antipsychotics Episode Overview Extrapyramidal syndromes are a common complication of antipsychotic medications. First line treatment is benztropine or diphenhydramine. Lorazepam is used in
More informationPARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada
PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationMirtazapine improves visual hallucinations in Parkinson s disease: a case report
bs_bs_banner doi:10.1111/j.1479-8301.2012.00432.x PSYCHOGERIATRICS 2013; 13: 103 107 CASE REPORT Mirtazapine improves visual hallucinations in Parkinson s disease: a case report Kenji TAGAI, Tomoyuki NAGATA,
More informationEuropean Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations
July 6, 2016 European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations Porto, 5 July 2016 BIAL announced that the medicinal product ONGENTYS
More informationParkinson s Disease Update
Parkinson s Disease Update Elise Anderson MD Providence Center for Parkinson s Disease October 26, 2017 11/6/2017 1 Disclosures GE Speaker, DaTSCAN 11/6/2017 2 Outline PD diagnosis Motor and nonmotor symptoms
More informationSP.236 / ESG.SP236 Exploring Pharmacology Spring 2009
MIT OpenCourseWare http://ocw.mit.edu SP.236 / ESG.SP236 Exploring Pharmacology Spring 2009 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. Atypical (2
More informationWhat is Parkinson s Disease?
2018 Update in Parkinson s Disease: Treatments and Future Plans Arita McCoy, MSN, CRNP Johns Hopkins Parkinson s Disease and Movement Disorder Center A National Parkinson Foundation Center of Excellence
More information